Research declarations
Patent Rights, Pandemic Equity and the Limits of the WTO COVID-19 Vaccine Decision
Yuvraj · Published version 1
These declarations reproduce the recorded publication version. They are author disclosures, not independent verification by The Legal Gazette.
Research declarations
Funding and sponsor involvement
No external funding. This research was independently undertaken without financial sponsorship, institutional grants, or external sponsor involvement.
Competing interests
The author is associated with The Legal Gazette, the intended publisher of this manuscript. No other financial, professional, institutional or personal competing interests are declared.
Author contributions
Yuvraj is the sole author and was responsible for conceptualization, research design, methodology, investigation, collection and analysis of legal materials, comparative analysis, drafting, revision, and final approval of the manuscript.
Originality and related publications
This manuscript is based on and substantially revises my earlier legal blog article titled “Impact of IP Rights on COVID-19 Vaccine,” published on 1 April 2022 on my Quora legal blog under Intellectual Property Law: https://intellectualpropertylaw.quora.com/Impact-of-IP-Rights-on-COVID-19-vaccine. The present manuscript, titled “Patent Rights, Pandemic Equity and the Limits of the WTO COVID-19 Vaccine Decision: Reassessing the TRIPS Waiver Debate from 2020 to 2026,” has been extensively restructured, revised, and updated. It incorporates subsequent WTO developments, the distinction between the 2020 waiver proposal and the 2022 Ministerial Decision, expanded doctrinal analysis, comparative perspectives, and developments in pandemic preparedness and technology transfer. The earlier blog publication is disclosed transparently. This manuscript is submitted as a substantially revised scholarly work and is not concurrently under consideration elsewhere.
Methods and legal currency
This research adopts a doctrinal and comparative legal methodology. It examines primary legal sources, including the TRIPS Agreement, the Doha Declaration on TRIPS and Public Health, WTO proposals, ministerial decisions, and relevant institutional materials from the WTO and WHO. Secondary sources include selected academic literature and legal commentary. The analysis focuses on international intellectual property and public health law, with particular reference to India and comparative developments in other jurisdictions. The legal position has been reviewed as of 1 November 2026. The manuscript does not claim empirical findings and does not rely on interviews, surveys, or original statistical research.
Limitations
The manuscript is limited to the legal and policy dimensions of intellectual property protection and equitable access to COVID-19 vaccines, particularly within the WTO/TRIPS framework. It does not undertake an exhaustive empirical assessment of vaccine production, pricing, procurement, distribution, or the measurable effects of the 2022 Ministerial Decision. Its comparative analysis is selective, and legal frameworks across jurisdictions are not treated as interchangeable. The conclusions are doctrinal and normative rather than based on original empirical data.
Ethics and participant protections
This is desk-based doctrinal and comparative legal research using publicly accessible legal instruments, institutional documents, judicial and academic materials, and published sources. It does not involve human participants, interviews, surveys, personal records, identifiable private data, or animal research. Accordingly, institutional ethical approval and participant consent were not applicable.
Data and materials availability
The research relies on publicly accessible legislation, international legal instruments, WTO and WHO documents, and published academic literature, all identified through citations and references. No original dataset was generated. Access to third-party materials remains subject to applicable copyright, licensing, and database terms.
AI and writing assistance
Generative AI tools were used for editorial assistance, language refinement, organisation, and writing support during the revision of the manuscript. The author independently reviewed and verified the manuscript, including its legal arguments, sources, citations, and conclusions, and accepts full responsibility for its accuracy, originality, integrity, and final content. AI tools are not authors of this work.